Literature DB >> 27135392

Long-Term Risk for Device-Related Complications and Reoperations After Implantable Cardioverter-Defibrillator Implantation: An Observational Cohort Study.

Isuru Ranasinghe, Craig S Parzynski, James V Freeman, Rachel P Dreyer, Joseph S Ross, Joseph G Akar, Harlan M Krumholz, Jeptha P Curtis.   

Abstract

BACKGROUND: Long-term nonfatal outcomes after implantable cardioverter-defibrillator (ICD) placement are poorly defined.
OBJECTIVE: To determine the long-term risk for ICD-related complications requiring reoperation or hospitalization and reoperation for reasons other than complications, and to assess associated patient and device characteristics.
DESIGN: Observational cohort study of ICD implantations from the National Cardiovascular Data Registry ICD registry linked with Medicare fee-for-service claims data.
SETTING: 1437 U.S. hospitals. PATIENTS: 114 484 patients aged 65 years or older (mean, 74.8 years [SD, 6.2]; 72.4% male) receiving an ICD for the first time from 2006 to 2010 (single-chamber, 19.8%; dual-chamber, 41.3%; cardiac resynchronization therapy with a defibrillator [CRT-D], 38.9%). MEASUREMENTS: Rate and cumulative incidence of ICD-related complications requiring reoperation or hospitalization and reoperation for reasons other than complications.
RESULTS: During a median follow-up of 2.7 years (interquartile range, 1.8 to 3.9 years), 40 072 patients died, representing 12.6 (95% CI, 12.5 to 12.7) deaths per 100 patient-years of follow-up. When the risk for death was accounted for, there were 6.1 (CI, 6.0 to 6.2) ICD-related complications per 100 patient-years that required reoperation or hospitalization and 3.9 (CI, 3.8 to 4.0) reoperations per 100 patient-years for reasons other than complications. Overall, 10 patients had complications or reoperation per 100 patient-years of follow-up. Younger age at implantation (65 to 69 vs. >85 years) (hazard ratio [HR], 1.55 [CI, 1.43 to 1.69]), receipt of a CRT-D device (HR, 1.38 [CI, 1.31 to 1.45]) versus a single-chamber device, female sex (HR, 1.16 [CI, 1.12 to 1.21]), and black race (HR, 1.14 [CI, 1.05 to 1.23]) were associated with the greatest increased risks for ICD-related complications. LIMITATION: The analysis was limited to Medicare fee-for-service patients aged 65 years or older.
CONCLUSION: Patients have a high rate of device-related complications and reoperation for other causes after ICD implantation. Risks of ICD implantation and strategies to reduce them should be actively considered before implantation. PRIMARY FUNDING SOURCE: American College of Cardiology Foundation's National Cardiovascular Data Registry.

Entities:  

Year:  2016        PMID: 27135392     DOI: 10.7326/M15-2732

Source DB:  PubMed          Journal:  Ann Intern Med        ISSN: 0003-4819            Impact factor:   25.391


  21 in total

Review 1.  Current Review of Implantable Cardioverter Defibrillator Use in Patients With Left Ventricular Assist Device.

Authors:  Jacinthe Boulet; Emmanuelle Massie; Blandine Mondésert; Yoan Lamarche; Michel Carrier; Anique Ducharme
Journal:  Curr Heart Fail Rep       Date:  2019-12

2.  Is Time From Last Hospitalization for Heart Failure to Placement of a Primary Prevention Implantable Cardioverter-Defibrillator Associated With Patient Outcomes?

Authors:  Andrew P Ambrosy; Craig S Parzynski; Daniel J Friedman; Marat Fudim; Adrian F Hernandez; Gregg C Fonarow; Frederick A Masoudi; Sana M Al-Khatib
Journal:  Circulation       Date:  2018-12-11       Impact factor: 29.690

Review 3.  [Current impact of cardiac implantable electronic devices].

Authors:  J Kuschyk; B Rudic; M Borggrefe; I Akin
Journal:  Herz       Date:  2017-04       Impact factor: 1.443

4.  Association of Physician Specialty With Long-Term Implantable Cardioverter-Defibrillator Complication and Reoperations Rates.

Authors:  Philip W Chui; Yongfei Wang; Isuru Ranasinghe; Teferi Y Mitiku; Arnold H Seto; Lindsey Rosman; Rachel Lampert; Karl E Minges; Alan D Enriquez; Jeptha P Curtis
Journal:  Circ Cardiovasc Qual Outcomes       Date:  2019-06-12

Review 5.  Prophylactic implantable cardioverter defibrillator in heart failure: the growing evidence for all or Primum non nocere for some?

Authors:  Khang-Li Looi; Nigel Lever; Anthony Tang; Sharad Agarwal
Journal:  Heart Fail Rev       Date:  2017-05       Impact factor: 4.214

6.  The impact of government-mandated shared decision-making for implantable defibrillators: A natural experiment.

Authors:  Birju R Rao; Faisal M Merchant; Eli R Abernethy; David H Howard; Daniel D Matlock; Neal W Dickert
Journal:  Pacing Clin Electrophysiol       Date:  2022-01-13       Impact factor: 1.976

7.  Can machine learning complement traditional medical device surveillance? A case study of dual-chamber implantable cardioverter-defibrillators.

Authors:  Joseph S Ross; Jonathan Bates; Craig S Parzynski; Joseph G Akar; Jeptha P Curtis; Nihar R Desai; James V Freeman; Ginger M Gamble; Richard Kuntz; Shu-Xia Li; Danica Marinac-Dabic; Frederick A Masoudi; Sharon-Lise T Normand; Isuru Ranasinghe; Richard E Shaw; Harlan M Krumholz
Journal:  Med Devices (Auckl)       Date:  2017-08-16

8.  Incidence and Risk Factors for Permanent Pacemaker Implantation Following Mitral or Aortic Valve Surgery.

Authors:  Gil Moskowitz; Kimberly N Hong; Gennaro Giustino; A Marc Gillinov; Gorav Ailawadi; Joseph J DeRose; Alexander Iribarne; Alan J Moskowitz; Annetine C Gelijns; Natalia N Egorova
Journal:  J Am Coll Cardiol       Date:  2019-11-26       Impact factor: 24.094

9.  Quantifying the utilization of medical devices necessary to detect postmarket safety differences: A case study of implantable cardioverter defibrillators.

Authors:  Jonathan Bates; Craig S Parzynski; Sanket S Dhruva; Andreas Coppi; Richard Kuntz; Shu-Xia Li; Danica Marinac-Dabic; Frederick A Masoudi; Richard E Shaw; Frederick Warner; Harlan M Krumholz; Joseph S Ross
Journal:  Pharmacoepidemiol Drug Saf       Date:  2018-06-12       Impact factor: 2.890

10.  Locating Order-Disorder Phase Transition in a Cardiac System.

Authors:  Hiroshi Ashikaga; Ameneh Asgari-Targhi
Journal:  Sci Rep       Date:  2018-01-31       Impact factor: 4.379

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.